Mesirow Financial Investment Management Inc. Has $6.24 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Mesirow Financial Investment Management Inc. cut its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 53.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 38,288 shares of the company's stock after selling 44,010 shares during the quarter. Mesirow Financial Investment Management Inc.'s holdings in Zoetis were worth $6,239,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ZTS. Mission Wealth Management LP raised its position in shares of Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock worth $479,000 after buying an additional 59 shares in the last quarter. Hancock Whitney Corp raised its position in shares of Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company's stock worth $3,628,000 after buying an additional 61 shares in the last quarter. Strategy Asset Managers LLC raised its position in shares of Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company's stock worth $356,000 after buying an additional 62 shares in the last quarter. VeraBank N.A. raised its position in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after buying an additional 62 shares in the last quarter. Finally, Procyon Advisors LLC raised its position in shares of Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock worth $768,000 after buying an additional 63 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Remove Ads

Zoetis Trading Up 1.8 %

Shares of Zoetis stock traded up $3.09 during trading on Friday, hitting $170.34. The stock had a trading volume of 3,296,788 shares, compared to its average volume of 3,274,650. The stock has a 50 day simple moving average of $166.72 and a 200 day simple moving average of $176.78. The company has a market capitalization of $76.28 billion, a PE ratio of 31.14, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is presently 36.56%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, Piper Sandler lifted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of "Buy" and a consensus target price of $215.90.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.